Last reviewed · How we verify
ETV；TDF；ADV
At a glance
| Generic name | ETV；TDF；ADV |
|---|---|
| Also known as | entecavir;tenofovir disoproxil fumarate;adefovir |
| Sponsor | Huashan Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Extension Study of Carvedilol RCT Study (NA)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients (PHASE2)
- Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides (PHASE4)
- The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection (PHASE4)
- An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETV；TDF；ADV CI brief — competitive landscape report
- ETV；TDF；ADV updates RSS · CI watch RSS
- Huashan Hospital portfolio CI